(NVET) (NVET) Stock Price, News & Analysis

Company Overview

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Key Stats

• Today's Range: $6.72 to $6.72
• 50-Day Range: N/A
• 52-Week Range: $2.75 to $6.76
• Volume: N/A
• Average Volume: 38,104 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NVET Stock Analysis - Frequently Asked Questions

How were (NVET)'s earnings last quarter?

(NVET) (NASDAQ:NVET) issued its quarterly earnings data on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02.

When did (NVET) IPO?

(NVET) (NVET) raised $58 million in an initial public offering (IPO) on Thursday, February 5th 2015. The company issued 4,000,000 shares at a price of $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.

What other stocks do shareholders of (NVET) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (NVET) investors own include Frontline (FRO), Achillion Pharmaceuticals (ACHN), Anthera Pharmaceuticals (ANTH), Sphere 3D (ANY), Arena Pharmaceuticals (ARNA), Yamana Gold (AUY) and BioLineRx (BLRX).

Company Calendar

• Last Earnings: 5/11/2017
• Today: 11/14/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NVET
• CUSIP: N/A
• CIK: 1618561
• Web: www.nexvet.com
• Phone: +353-1-2158100
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A